Source:http://linkedlifedata.com/resource/pubmed/id/16002425
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2005-10-5
|
pubmed:abstractText |
To obtain the large amount of T cells required for adoptive immunotherapy in a clinical setting, T-cell lifespan extension by human telomerase reverse transcriptase (hTERT) transduction is of particular interest. However, constitutive expression of hTERT is associated with malignant transformation and thus warrants a detailed evaluation of the safety of hTERT-transduced T cells before clinical application. In view of this, we performed an extensive cytogenetic analysis of hTERT-transduced MART-1 (melanoma antigen recognized by T cell 1)-and human papillomavirus type 16 (HPV16) E7-specific human CD8+ cytotoxic T lymphocytes (CTLs), reactive against melanoma and cervical carcinoma, respectively. Our results, obtained by (spectral) karyotyping and array comparative genomic hybridization, showed the development of minor chromosomal aberrations in an hTERT-transduced MART-1-specific CTL clone, whereas severe clonal aberrations were detected in an hTERT-transduced HPV16 E7-specific CTL clone. Furthermore, hTERT transduction did not protect CTLs from immunosenescence, because the HPV16 E7-specific, hTERT-transduced CTL clone showed a decreased functional activity on prolonged culture. Although the general frequency of major chromosomal aberrations in hTERT-transduced CTLs and the in vivo significance of our observations remain still unclear at this point, the currently available data suggest that clinical application of hTERT-transduced CTLs should proceed with caution.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:BrinkAntoinette A T PAA,
pubmed-author:GeltinkRamon I KleinRI,
pubmed-author:HermsenMario A J AMA,
pubmed-author:HooijbergErikE,
pubmed-author:KueterEsther W MEW,
pubmed-author:MeijerChris J L MCJ,
pubmed-author:MeijerGerrit AGA,
pubmed-author:ScholtenKirsten B JKB,
pubmed-author:SchreursMarco W JMW,
pubmed-author:TijssenMarianneM,
pubmed-author:YlstraBaukeB
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
106
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2663-70
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16002425-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16002425-Cell Line,
pubmed-meshheading:16002425-Cell Survival,
pubmed-meshheading:16002425-Cytogenetic Analysis,
pubmed-meshheading:16002425-DNA-Binding Proteins,
pubmed-meshheading:16002425-Genome, Human,
pubmed-meshheading:16002425-Genomic Instability,
pubmed-meshheading:16002425-Humans,
pubmed-meshheading:16002425-Karyotyping,
pubmed-meshheading:16002425-Phenotype,
pubmed-meshheading:16002425-Telomerase,
pubmed-meshheading:16002425-Transduction, Genetic
|
pubmed:year |
2005
|
pubmed:articleTitle |
Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes.
|
pubmed:affiliation |
Department of Pathology, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|